Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
Clinical trial NCT02613598 · COMPLETED
Trial details
- NCT number
- NCT02613598
- Sponsor
- University of Michigan Rogel Cancer Center
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-05-12
- Primary completion
- 2021-06-07
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.